Altered cerebral gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by [11C]flumazenil positron emission tomography by Hasler, G et al.
University of Zurich
Zurich Open Repository and Archive
Winterthurerstr. 190
CH-8057 Zurich
http://www.zora.uzh.ch
Year: 2008
Altered cerebral gamma-aminobutyric acid type
A-benzodiazepine receptor binding in panic disorder determined
by [11C]flumazenil positron emission tomography
Hasler, G; Nugent, A C; Carlson, P J; Carson, R E; Geraci, M; Drevets, W C
Hasler, G; Nugent, A C; Carlson, P J; Carson, R E; Geraci, M; Drevets, W C (2008). Altered cerebral
gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by
[11C]flumazenil positron emission tomography. Archives of General Psychiatry, 65(10):1166-1175.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Archives of General Psychiatry 2008, 65(10):1166-1175.
Hasler, G; Nugent, A C; Carlson, P J; Carson, R E; Geraci, M; Drevets, W C (2008). Altered cerebral
gamma-aminobutyric acid type A-benzodiazepine receptor binding in panic disorder determined by
[11C]flumazenil positron emission tomography. Archives of General Psychiatry, 65(10):1166-1175.
Postprint available at:
http://www.zora.uzh.ch
Posted at the Zurich Open Repository and Archive, University of Zurich.
http://www.zora.uzh.ch
Originally published at:
Archives of General Psychiatry 2008, 65(10):1166-1175.
Altered cerebral gamma-aminobutyric acid type
A-benzodiazepine receptor binding in panic disorder determined
by [11C]flumazenil positron emission tomography
Abstract
CONTEXT: The benzodiazepine (BZD) receptor system has been implicated in the pathophysiologic
mechanism of panic disorder (PD) by indirect evidence from pharmacological challenge studies and by
direct evidence from single-photon emission computed tomography and positron emission tomography
neuroimaging studies. However, the results of previous neuroimaging studies are in disagreement,
possibly because of experimental design limitations related to sample size, matching between patients
and controls, and confounding medication effects. OBJECTIVE: To compare BZD receptor binding
between subjects with PD and healthy control subjects. DESIGN: Cross-sectional study for association.
SETTING: Psychiatric outpatient clinic of the National Institute of Mental Health. PARTICIPANTS:
Fifteen subjects with PD who were naïve to BZD drug exposure and were not receiving other drug
treatment, and 18 healthy controls. INTERVENTION: Images of BZD receptor binding were acquired
using positron emission tomography and flumazenil tagged with carbon 11. MAIN OUTCOME
MEASURES: The BZD receptor binding potential was assessed by a simplified reference tissue-tracer
kinetic model. RESULTS: The BZD receptor binding potential was decreased in multiple areas of the
frontal, temporal, and parietal cortices and was increased in the hippocampus/parahippocampal region in
subjects with PD vs controls. The most significant decrease was located in the dorsal anterolateral
prefrontal cortex (DALPFC); the most significant increase, in the hippocampus/parahippocampal gyrus.
These abnormalities were not accounted for by comorbid depression. In subjects with PD, the severity
of panic and anxiety symptoms correlated positively with BZD receptor binding in the DALPFC but
negatively with binding in the hippocampus/parahippocampal gyrus. CONCLUSIONS: These data
provide evidence of abnormal BZD-gamma-aminobutyric acid type A receptor binding in PD,
suggesting that basal and/or compensatory changes in inhibitory neurotransmission play roles in the
pathophysiologic mechanism of PD. They also provide evidence of an impairment of frontal-limbic
interaction in the modulation of anxiety responses, consistent with previous functional and structural
neuroimaging studies in PD.
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Context: The benzodiazepine (BZD) receptor system has been implicated in the 
pathophysiology of panic disorder (PD) through indirect evidence from pharmacological 
challenge studies and direct evidence from SPECT and PET neuroimaging studies. However, 
the results of previous neuroimaging studies are in disagreement, possibly because of 
experimental design limitations related to sample size, matching between patients and 
controls, and confounding medication effects. 
Objective: To compare BZD receptor binding between subjects with PD and healthy controls.  
Design: Cross-sectional study for association. 
Setting: Psychiatric outpatient clinic of the NIMH. 
Participants: Fifteen unmedicated subjects with PD who were naïve to BZD drug exposure, 
and 18 healthy controls. 
Intervention: Images of BZD receptor binding were acquired using PET and [11C]flumazenil. 
Main Outcome Measures: BZD receptor binding potential assessed by a simplified 
reference-tissue tracer-kinetic model. 
Results: The BZD receptor binding potential was decreased in multiple areas of the frontal, 
temporal and parietal cortices, and was increased in the hippocampal/parahippocampal region 
in PD subjects versus controls. The most significant decrease was located in the dorsal 
anterolateral prefrontal cortex (DALPFC) and the most significant increase was in the 
hippocampus/parahippocampal gyrus. These abnormalities were not accounted for by 
comorbid depression. In PD subjects the severity of panic and anxiety symptoms correlated 
positively with BZD receptor binding in the DALPFC, but negatively with binding in the 
hippocampus/parahippocampal gyrus. 
Conclusions: These data provide evidence for abnormal BZD-GABAA receptor binding in 
PD, suggesting that basal and/or compensatory changes in inhibitory neurotransmission play 
roles in the pathophysiology of PD. They also provide evidence for an impairment of frontal-
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limbic interaction in the modulation of anxiety responses, consistent with previous functional 
and structural neuroimaging studies of PD.
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 Panic disorder (PD) is a common pathological anxiety syndrome that may occur alone 
or in association with other psychiatric and medical conditions; in either case the presence of 
PD increases the risks for disability and mortality1-3. The gamma-amino butyric acid type A 
(GABAA)-benzodiazepine (BZD) receptor complex has been implicated in the 
pathophysiology of PD by various types of largely indirect evidence4. In healthy subjects, 
BZD receptor agonists show anxiolytic effects, and the BZD receptor inverse agonist FG 7142 
induces severe anxiety which resembles panic attacks and the biological characteristics of 
anxiety.5 In subjects with PD some high-potency BZD receptor agonists exert anti-panic 
effects. Nevertheless, subjects with PD show reduced neurophysiological sensitivity to BZD 
receptor agonists6 and increased behavioral sensitivity to the anxiogenic properties of the 
BZD receptor antagonist, flumazenil.7,8  
 Neuroreceptor imaging studies of BZD receptor binding have reported abnormalities 
in PD, but their results are in disagreement. Some discrepancies across studies may be 
attributable to experimental design limitations involving the matching of control samples, 
presence of confounding medication effects, small sample sizes, and technical aspects of 
image acquisition and analysis. Using SPECT and the selective BZD receptor ligand 
[123I]iomazenil, Brandt et al.9 found increased binding in 12 PD cases relative to 9 healthy 
controls in the “supraorbital” prefrontal cortex (PFC). This finding was confounded by 
medication effects, however, as most subjects were receiving psychotropic drugs, including 
antidepressant agents known to alter GABA-ergic transmission.10 Another SPECT-
[123I]iomazenil study compared BZD binding between 17 unmedicated PD subjects and 17 
healthy controls, and reported an increased left-to-right radiotracer uptake in the PFC of the 
PD subjects.11 A third SPECT-[123I]iomazenil study reported BZD receptor binding was 
decreased in the left hippocampus and precuneus, but increased in the caudate, cuneus, right 
dorsolateral PFC and left middle temporal gyrus, in 13 unmedicated PD subjects versus 16 
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healthy controls.12 The specificity of this study was limited, however, by prominent 
differences in gender composition between the control and PD samples, and the past 
drug/alcohol dependence history (in 30%) and benzodiazepine exposure in the PD sample. 
Other SPECT-[123I]iomazenil studies compared PD samples against control samples with 
epilepsy13 or dysthymic disorder14, but did not include healthy control (normative) samples.  
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Two studies assessed BZD receptor binding in PD using the more sensitive and higher 
resolution PET-[11C]flumazenil technique. In PD subjects naïve to BZD agonist drugs (n=7), 
Malizia and colleagues15  reported a global reduction in BZD receptor distribution volume 
(DV), with the most prominent reductions being evident in the right orbitofrontal cortex and 
insula in PD subjects relative to healthy controls. Cameron et al.16 found no significant 
difference in the global BZD binding, but confirmed the reduction in BZD receptor DV in the 
insula in 11 PD subjects (most of whom were naïve to benzodiazepine drug exposure) relative 
to healthy controls, and observed that this finding was largely accounted for by the PD 
subjects with comorbid depression. In both PET studies the interpretation of the results was 
limited by prominent imbalances in the gender ratio between the PD and control samples (see 
Discussion). 
  In summary, substantial indirect evidence exists for abnormalities of the central BZD 
receptor system in PD. Nevertheless, because of the inconsistency in the results and the 
methodological limitations of previous neuroreceptor imaging studies, the presence, location, 
and direction of abnormalities in BZD binding in PD remain unclear. The current study applied 
PET and [11C]flumazenil to compare BZD receptor binding between PD subjects who were 
naïve to benzodiazepine anxiolytics and free of current medication effects and past substance 
dependence, against a healthy control sample that was group-matched to the PD sample for age 
and gender.  
 
Hasler et al. 6 
METHODS 109 
110 
111 
112 
113 
114 
115 
116 
117 
118 
119 
120 
121 
122 
123 
124 
125 
126 
127 
128 
129 
130 
131 
132 
133 
Subjects 
Participants included 15 volunteers who met DSM-IV criteria for current PD and had a 
PD Severity Scale (PDSS17) score of >6, and 18 healthy controls. Subjects were recruited 
through advertisements posted in local newspapers and on the NIH campus, and evaluated 
during screening visits in the outpatient psychiatry clinic of the NIH Clinical Center. 
Psychiatric diagnoses were established by both an unstructured interview with a psychiatrist 
and the Structured Clinical Interview for the Diagnostic and Statistical Manual of Mental 
Disorders, Fourth Edition.18,19 The family history of psychiatric disorders was assessed using 
the Family Interview for Genetic Studies.20 The clinical evaluation also included physical 
examination, electrocardiogram, neuromorphological MRI scanning and laboratory tests, 
including liver and kidney function tests, hematology profile, thyroid function tests, urine 
analysis, and toxicology (urine drug screen). Behavioral ratings included the PDSS, the 
Hamilton Depression Rating Scale (HDRS), the Hamilton Anxiety Rating Scale (HARS), the 
Panic Symptom Scale (PSS)21 and the Beck Anxiety Inventory (BAI). 
Exclusion criteria for all subjects included current medical or neurological disorders, 
lifetime exposure to benzodiazepine agonist drugs, exposure to psychotropic medications 
within 4 weeks of scanning (8 weeks for fluoxetine), lifetime history of substance use 
disorders, current nicotine use, pregnancy, and claustrophobia. An additional exclusion 
criterion for the PD subjects was having a current major psychiatric disorder other than PD, 
excepting major depressive disorder (MDD) and generalized anxiety disorder (GAD), which 
commonly occur comorbidly with PD1. Additional exclusion criteria for the controls included 
having a personal or first-degree family history of a major psychiatric disorder. After 
providing a full explanation of the study purpose and procedures, written consent was 
obtained as approved by the NIMH Institutional Review Board.  
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Positron Emission Tomography 134 
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PET scans were acquired as subjects rested with eyes closed using a GE Advance 
scanner with septa retracted (35 contiguous slices; 4.25mm plane separation; reconstructed 3D 
spatial resolution=6-7mm full-width at half-maximum). A transmission scan was acquired to 
correct for attenuation. Following transmission scanning, a target dose of 20 mCi of high 
specific activity [11C]-flumazenil was injected. The upper limit to the injection mass of [11C]-
flumazenil was set at 9 µg per 70 Kg in all studies. A 60-min dynamic emission image of the 
brain was initiated at injection. Subject motion correction during the PET acquisition was 
performed with a mutual-information registration of each scan time-frame to a standard frame 
before attenuation correction. Based on the calculated motion, the transmission images were 
resliced and projected for final reconstruction and realignment. 
To provide an anatomical framework for analysis of the PET images, structural MRI 
scans were acquired using a 3.0 Tesla scanner (Signa; GE Medical Systems, Waukesha, WI), 
and a T1-weighted pulse sequence (MP-RAGE; voxel size=0.9x0.9x1.2 mm). PET images 
were registered to the individual’s MRI with a mutual information algorithm. 
Statistical Analysis  
Binding potential (BP) images were created using the 2-step version of the simplified 
reference tissue model (SRTM2)22. Input kinetics for the reference tissue were derived from 
the pons (delimited on the MR image), where [11C]flumazenil binding predominantly reflects 
free and nonspecifically bound radiotracer23. The BP images (already transformed to MR 
space) were then transformed to a common space (the Montreal Neurological Institute [MNI] 
template) and SPM2 software (Wellcome Department of Imaging Neuroscience, UCL, 
London, UK). The PET images then were filtered using a 10-mm gaussian smoothing kernel 
to compensate for misalignment error arising during spatial normalization and individual 
anatomical variation.  
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Using SPM2, the [11C]flumazenil BP values were compared between groups in a 
voxel-wise analysis using a two-sample t-test model.  The SPM was thresholded at p<0.05 
uncorrected to facilitate the delineation of significant clusters. Voxels among the three most 
significant in each cluster, independently significant at p≤0.001 uncorrected, were reported. 
The p-values were corrected for multiple comparisons using the cluster test and voxel level 
family-wise error tests24, and voxels where the differences remained significant after applying 
corrections were additionally indicated.  The coordinates of each voxel were converted to the 
stereotaxic spatial array of Talairach and Tournoux25 using a linear transformation 
(http://imaging.mrc-cbu.cam.ac.uk/downloads/MNI2tal/mni2tal.m). 
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To assess the specificity of abnormalities in BZD receptor binding, post hoc voxel-
wise analyses were performed to separately compare the PD subgroups with versus without a 
past history of depression against the healthy control group and against each other. Because 
the statistical power for detecting differences relative to the controls was reduced in these 
smaller sample sizes, the significance threshold was lowered to p<0.005 for these exploratory 
analyses.  Age and gender were included as covariates in these subgroup analyses to adjust for 
differences in these parameters between subgroups. 
In regions where differences in BP between the entire PD and control samples 
remained significant after applying corrections for multiple testing, the relationships between 
BP and panic, anxiety and depression ratings were assessed post hoc. For each region, the BP 
values were mean centered and adjusted for baseline effects.  Values from each PD subject 
were correlated with the PDSS, HAMD, and HAMA scores by computing Pearson Product 
Moment Correlation Coefficients using SPSS software (SPSS Inc., Chicago, IL). Correlations 
with r>0.5 and p<0.05 were reported in these exploratory analyses. 
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RESULTS 183 
184 
185 
Table 1 shows demographic and clinical characteristics of the study samples. Of the 
PD subjects, ten were naïve to psychotropic drugs and five had been medication-free for a 
mean of 35+35 mos (range:4-96). Eight PD subjects also had a history of MDD (mean 
age=41.3
186 
+11.0, 63% female), while seven denied ever meeting criteria for a major depressive 
episode (mean age=27.9, 86% female). One subject met criteria for PD with agoraphobia. No 
PD subject experienced a panic attack during PET scanning. 
187 
188 
189 
190 The mean [11C]flumazenil dose administered did not differ significantly between the 
PD and control groups (19.7+1.0 and 20.0+0.6 mCi, respectively). The specific activity in 
mCi/umol at time of injection was 1672
191 
+493 (range:1036-2318) in the PD group and 
1539
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+322 (range:584-2134) in the controls (p=0.38).  193 
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The PD subjects showed lower [11C]flumazenil BP than controls in the bilateral dorsal 
anterolateral PFC (DALPFC; 13% reduction on the ride side at corrected p<0.05), right 
frontal polar cortex, right dorsolateral PFC, bilateral precentral gyrus (19% reduction on the 
ride side at cluster-level corrected p<0.001), right postcentral gyrus, right superior temporal 
gyrus, anterior cingulate cortex (ACC), right superior parietal cortex and left superior 
occipital gyrus (table 2; figure 1). The PD subjects showed higher BP (by 16% on the right 
side and by 13% on the left side) than controls in the hippocampus/parahippocampal gyrus 
bilaterally and the left dorsolateral PFC (table 2; figure 2). The increase in the right and left 
hippocampal/parahippocampal cortex remained significant after correcting for multiple 
testing. 
The post hoc subgroup analyses (tables 3,4) showed that relative to healthy controls, 
both the PD alone subjects and the PD plus MDD subjects showed reduced BP in the 
DALPFC, bilaterally. The subjects with PD alone showed lower BP in the infralimbic cortex 
and higher BP in the right parahippocampal cortex than both healthy controls and PD plus 
MDD subjects. The PD plus MDD subjects showed higher BP than both healthy controls and 
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PD alone subjects in the right middle temporal gyrus. Finally, the subjects with PD alone 
showed lower BP in the bilateral frontal polar cortex and left superior frontal gyrus, and lower 
BP in the right inferior temporal gyrus, relative to healthy controls, but did not differ from the 
PD plus MDD subjects in these regions.  
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To correlate illness severity ratings with BZD receptor binding, the regional BP values 
in the DALPFC and the hippocampus/parahippocampal cortex were obtained for each PD 
subject by defining regional templates on the statistical parametric images. The right 
DALPFC template was defined from the parametric image for the Control>PD contrast to 
encompass the voxel containing the peak t-value (table 2) and contiguous voxels in the same 
cluster for which t corresponded to p<0.0001. This template encompassed 466 voxels (3.73 
ml) surrounding the peak voxel t-value at x=21, y=49, z=32. In this region the BP values 
correlated positively with panic, anxiety and depression severity ratings (PDSS:r=0.696, 
p=0.006; HAMA:r=0.585, p=0.028; HAMD:r=0.563, p=0.036).  
In the hippocampal/ parahippocampal region the BP values for individual PD subjects 
were obtained from templates defined on the PD>Control contrast to encompass the peak 
voxel t-value (right: x=30, y= -22, z= -17; left: x= -26, y= -24, z= -16; table 2) and the 
contiguous voxels in the same cluster for which t corresponded to p<0.005 (the t-values 
generally were smaller in these regions than in the right DALPFC [table 2], so a lower 
statistical threshold was applied to encompass a comparable tissue volume). These templates 
encompassed 494 voxels (3.95 ml) and 283 voxels (2.26 ml) in the right and left hippocampal/ 
parahippocampal regions, respectively.  In these regions BP correlated negatively with panic, 
anxiety and depression severity ratings on both the left (PDSS: r=-0.589, p=0.027; HAMD: 
r=-0.623, p=0.017; HAMA: r=-0.535, p=0.049) and right sides (PDSS: r=-0.621, p=0.018; 
HAMD: r=-0.533, p=0.05; HARS: r=-0.545, p=0.044). Rating scales plotted versus mean 
centered and adjusted binding potential appear in Figure 3.  
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Finally, although gender-based subsamples were too small to assess sex-differences 
within diagnostic groups for males, voxelwise analysis limited to females alone replicated the 
main findings from the entire sample. There was a similar reduction in 11C-flumazenil binding 
in women with PD in right precentral gyrus (t=4.98) and DALPFC (t=4.21). In addition, areas 
of elevated BP in PD women versus control women were evident in the right (t=4.58) and left 
parahippocampal gyri (t=2.98). Across the whole sample (PD plus control), no significant 
gender difference in flumazenil BP was evident in the ROI defined in the right DALPFC, 
right precentral gyrus, or bilateral parahippocampal gyrus over the areas where the groups had 
differed most in the initial voxel-wise analysis. 
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COMMENT 
The BZD receptor binding was decreased in several areas of the frontal, temporal and 
parietal cortices, but was increased in the hippocampal/parahippocampal region in PD 
subjects versus healthy controls. Comorbid depression did not account for these differences, 
based on post hoc comparisons involving PD subjects with no history of major depressive 
episodes. In PD subjects the BP values and the severity of panic and anxiety symptoms were 
correlated positively in the DALPFC, but negatively in the bilateral hippocampus/ 
parahippocampal gyrus. 
Our results appear partly consistent with those of previous PET-[11C]flumazenil 
studies which also selected PD cases who were naïve to benzodiazepine anxiolytics. Similar 
to our results (table 2), Malizia et al.15 reported that BZD receptor binding was abnormally 
decreased in PD in areas of the frontal, anterior cingulate, temporal, parietal and occipital 
cortices. Our finding that BZD binding was reduced in the right insula in PD subjects with 
comorbid depression versus healthy controls appeared compatible with the reports of 
Cameron et al.16 and Malizia et al.15 that BZD binding was abnormally decreased in the right 
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insula in PD, as Cameron et al. showed this difference was largely attributable to PD cases 
with comorbid depression. 
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In contrast to our results in the parahippocampal gyrus/ ventral hippocampus, 
however, Cameron et al.16 observed no difference in this area and Malizia et al.15 found 
reduced BZD receptor binding in a volume placed over the amygdala and adjacent 
hippocampus. Methodological issues may have contributed to these discrepancies. Firstly, in 
our data the amygdala showed no evidence of abnormal BZD binding (figure 2) and the 
affected area in the vicinity of the hippocampus localized to the interface between 
parahippocampal gyrus and anteroventral hippocampus, so the volume assessed by Malizia et 
al. may have diluted or missed this effect. Secondly, the prominent imbalance in gender ratios 
of the PD and control samples in these previous PET studies may have contributed to Type II 
error (in Malizia et al. 3 of 7 patients were females while all 7 controls were male; in 
Cameron et al. 9 of 11 patients were female while 8 of 21 controls were female), although no 
study has been sufficiently powered to assess gender effects on BZD receptor binding in PD. 
Thirdly, the sample sizes in these studies were small, so the failure to replicate results across 
studies may reflect Type II error, particularly since our post hoc assessments suggested that 
the elevated BZD receptor binding in the hippocampal/parahippocampal region was specific 
to PD subject without comorbid depression (each of the previous PET studies included only 
six of such cases). The conservative image analysis approach of Cameron et al.16 further 
increased the chance of Type II error.  
With respect to SPECT-[123I]iomazenil studies, our findings appear compatible with 
Kuikka et al.11 who reported increased left-to-right radiotracer uptake in the PFC of PD 
subjects, as we found abnormally reduced [11C]flumazenil binding in several right PFC areas, 
together with increased binding in a left dorsolateral PFC area in PD. In contrast, our results 
appeared to disagree with Bremner et al.12, who reported decreased BZD binding in left 
hippocampus and increased binding in right dorsolateral PFC. Nevertheless, the peak 
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difference in BZD receptor binding reported in the hippocampus in their study was situated 2 
cm medial and dorsal to the area where we found abnormally increased [11C]flumazenil 
binding (e.g., the stereotaxic coordinates for the “hippocampal” abnormality reported by 
Bremner et al. were: x=12, y= -26, z= -4, which localizes to the midbrain in Talairach and 
Tournoux 25). Moreover, most of the PD subjects studied by Bremner et al. were experiencing 
panic attacks at the time of scanning, raising the possibility that state-dependent changes in 
BZD receptor binding, excessive movement during imaging, or lower specific activity 
radioligand dose accounted for the dissimilar results across studies. Bremner et al. also 
included subjects with past histories of benzodiazepine use and alcohol/drug dependence, 
whereas we excluded such cases, and their PD and control samples were not matched for 
gender. Finally, SPECT affords lower sensitivity and spatial resolution than PET, limitations 
which would have reduced the specificity of measures in small structures such as the 
hippocampus. 
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Although most previous studies did not find correlations between anxiety symptom 
scores and BZD receptor binding,9,11,15,16 one study reported a negative correlation between 
PFC BZD receptor binding and Panic Attack Symptom Scale scores.26 Another study of 
subjects with various anxiety disorders (most had PD) showed a positive correlation between 
lateral and medial PFC BZD receptor binding and Spielberg State Anxiety scores.27 These 
findings appear compatible with ours regarding the direction of correlation in the DALPFC, 
although they used a state anxiety measure while we used a score of panic severity over the 
past one-month. 
Strengths of our study included the relatively large sample size, the exclusion of 
subjects with current psychotropic drug use or lifetime history of BZD exposure, the relatively 
close matching of PD and control samples with respect to age and gender, the relatively 
higher spatial resolution and sensitivity afforded by the PET-[11C]flumazenil technique, and 
the improved accuracy of spatial transformation and localization achieved via PET-MRI co-
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registration. Moreover, we limited the injected mass of flumazenil to <9 µg per 70 kg, and the 
specific activities of the injected [11C]flumazenil injected in our study (mean values exceeded 
1500 mCi/µmol) were higher than those used in previous studies of PD. Lassen et al. reported 
that a 10 mCi injection of [11C]flumazenil at a specific activity of 450 Ci/mmol (0.02 µmol or 
7 µg) resulted in a BZD receptor occupancy of 0.7% at 30 min28. Based upon these data our 
injected mass of <9 µg per 70 kg would have occupied <1% of brain BZD receptors.  
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The high prevalence rate of comorbid MDD in our PD sample was consistent with that 
of community studies demonstrating strong associations between depression and panic.29 
Moreover, the sample size allowed evaluation of the specificity of the findings in PD with 
respect to comorbid depression. 
Several limitations of our methods merit comment. The sensitivity of our results may 
have been reduced by the inability to exclude “healthy controls” with a latent vulnerability to 
PD. In addition, our PD sample overrepresented females compared to the sex ratio of PD in 
the general population1, which may reduce the generalizability of the results. In addition, our 
experiment’s cross-sectional design could not distinguish whether abnormalities in BZD 
receptor binding reflected a biological vulnerability for PD or a consequence of illness. 
Finally, to obviate the need for arterial cannulation we applied a simplified reference 
tissue model for obtaining BP. Simplified reference tissue modeling approaches with pons as 
reference tissue were validated against more invasive approaches that used arterial plasma 
input functions for deriving [11C]flumazenil BP.23,30 The BP values obtained using these two 
approaches were highly correlated (r=0.960 to 0.998).23,30  
The pons proved superior to the other reference regions tested for estimating free and 
nonspecifically bound [11C]flumazenil with respect to the robustness of model fits, reliability 
and lower bias27,30,31. Nevertheless, a moderate level of [11C]flumazenil binding in the pons is 
receptor specific.23,32 A limitation of applying reference tissue models for comparing 
[11C]flumazenil binding between groups, therefore, is that a difference in regional BP may 
Hasler et al. 15 
reflect either abnormal BZD receptor binding in the region-of-interest or abnormal DV in the 
pons. To address this issue we relied upon the consistent finding from previous studies that 
sampled arterial blood that the BZD receptor DV in the pons did not differ significantly 
between healthy control and either PD samples12,15,16 or mixed anxiety disordered samples 
composed predominantly of PD cases.27 Nevertheless, it is noteworthy that since the SRTM2 
model ratios tracer binding in target tissues to that in the reference tissue, differences in the 
pons DV between groups could influence the results in one direction only, and thus could not 
account for both abnormal increases in some regions and abnormal decreases in other regions 
in PD. 
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Furthermore, while the pons is relatively small, partial volume effects on a volume-of-
interest of this size (range, 4.49-8.25 mL) are minor in images of 6-7 mm spatial resolution. 
The spherical properties of the pons also limit partial volume effects due to contamination 
with cortical gray matter. The ability to obtain measures from the pons with relatively little 
partial volume effect has been considered an advantage of this reference region over others 
assessed in the literature. Nevertheless, it is noteworthy that any potential underestimation in 
the pons tracer uptake associated with partial volume effects would presumably affect the 
image data in patients and controls similarly, and thus would not be expected to result in 
differences in BP between groups.  
 Based largely on preclinical evidence, the pathophysiology of PD was hypothesized 
to involve a “fear network” centered in the amygdala and its interaction with the 
hippocampus, medial PFC and brainstem.33 This model posited that reduced cortical control 
(medial PFC), dysregulated contextual fear learning (hippocampus), impaired extinction 
learning (infralimbic cortex) and hyperactive anxiogenic limbic and paralimbic brain areas 
(amygdala, hypothalamus, periaqueductal grey34,35) contributed to the pathophysiology of PD. 
Compatible with this model we found abnormalities in BZD receptor binding in PD in the 
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hippocampus/parahippocampal cortex and medial PFC structures such as the DALPFC 
(Brodmann Area [BA] 9), frontal polar cortex (BA 10), ACC and infralimbic cortex.34  
362 
363 
364 
365 
366 
367 
368 
369 
370 
371 
372 
373 
374 
375 
376 
377 
378 
379 
380 
381 
382 
383 
384 
385 
386 
387 
Reduced BZD receptor binding in the medial PFC may reflect down-regulation of 
BZD receptor expression or sensitivity.36 Such effects may result from repeated stress 
associated with recurrent panic,37 as preclinical studies show that exposure to acute 
inescapable stress results in decreased cortical BZD receptor binding.36,37 In PD subjects acute 
panic attacks resulted in pronounced changes in neurosteroid concentrations that were 
interpreted to indicate decreased GABA-ergic tone.38 Moreover, the basal hypersecretion in 
PD subjects of the neurosteroids progesterone and its metabolites, pregnenolone and 
allopregnanolone, which appear to exert anxiolytic effects via positive allosteric modulation 
of GABAA receptors,39 is hypothesized to reflect a compensatory response to blunted GABAA 
receptor sensitivity in PD.40 Finally, reduced brain GABA concentrations were reported in 
magnetic resonance spectroscopy studies of PD,41,42 which also may be associated with 
altered BZD receptor binding. 
The most significant reductions in BZD receptor binding were located in the right 
DALPFC. This region corresponds to BA 9, a medial PFC region that shares extensive 
anatomical connectivity to the PAG.34,35 The PAG was implicated in preclinical models of 
PD,43 as stimulation of the dorsolateral and lateral columns of the PAG produced fear 
behaviors and sympathetic autonomic arousal.44,45 Another medial PFC region where BZD 
receptor binding was decreased in PD (table 2) was the ACC. Hemodynamic activity in the 
ACC increased during a variety of anxiety states elicited in healthy or anxiety disordered 
subjects,46 including pentagastrin-induced panic attacks in PD subjects.47 
The specific association between pure PD (i.e., without comorbid MDD; table 3) and 
reduced BZD receptor binding in another medial PFC structure, the infralimbic cortex, is 
noteworthy because projections from this region to the amygdala are implicated in fear 
extinction learning.48 Moreover, in rats pairing conditioned threat cues with brief electrical 
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stimulation of the infralimbic cortex reduces fear.49 It remains unclear whether reduced BZD-
GABAA receptor binding in this region in PD would be associated with dysregulated 
extinction learning, or alternatively, might reflect a compensatory mechanism for enhancing 
neuronal transmission to the amygdala related to fear inhibition.48 Since exposure-based 
treatment of PD presumably depends upon extinction learning, dysfunction involving the 
infralimbic cortex may hold clinical relevance in PD. 
388 
389 
390 
391 
392 
393 
394 
395 
396 
397 
398 
399 
400 
401 
402 
403 
404 
405 
406 
407 
408 
409 
410 
411 
412 
413 
This is the first study to report increased BZD receptor binding in the 
parahippocampal gyrus, although spatial resolution limitations precluded our ability to 
definitively resolve this cortex from adjacent hippocampus. This abnormality appeared to be 
specifically associated with PD, and not with comorbid depression. The parahippocampal 
gyrus and hippocampus previously were implicated in functional and structural neuroimaging 
studies of PD. Reiman et al.50 reported an abnormally low left-right ratio of parahippocampal 
blood flow at rest in PD subjects who were sensitive to lactate-induced panic. De Cristofaro et 
al.51 found a significant decrease in perfusion in the hippocampus bilaterally in PD subjects. A 
neuromorphometric MRI study found decreased gray matter density in the parahippocampal 
cortex of PD subjects versus controls52. Increased BZD receptor binding in the 
parahippocampal region conceivably may reflect a compensatory mechanism in PD. The 
parahippocampal gyrus and anterior ventral hippocampus (i.e., subiculum) share extensive 
anatomical projections with the amygdala and medial PFC regions that form the visceromotor 
network.34 
The results of the correlational analyses appear paradoxical since they run counter to 
the group differences. One hypothesis that could reconcile the direction of both the group 
differences and the clinical correlations would hold that changes in BZD receptor binding in 
PD reflect effective compensatory changes. In this model, higher BZD receptor binding in the 
hippocampus would result in lower anxiety levels in PD subjects by enhancing the inhibitory 
tone on limbic activity that facilitates emotional expression53. In contrast, lower BZD receptor 
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binding in the DALPFC would be associated with diminished anxiety because reduced 
inhibitory tone would enhance cortical modulation of anxiety-mediating limbic 
structures.48,54,55   
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 In conclusion, the abnormalities of BZD receptor binding in PD suggest that basal 
and/or compensatory changes in the GABAergic system are involved in the pathophysiology 
of PD. The reduced BZD binding in the PFC, superior temporal cortex and parieto-occipital 
cortex were compatible with preclinical evidence that stress down-regulates BZD receptor 
binding, and suggested the hypothesis that this effect may be an important mechanism in the 
pathogenesis of PD. These data encourage future studies designed to investigate genetic and 
environmental influences on BZD-GABAA receptors and interactions among BZD-GABAA, 
neurosteroids, monoaminergic and glutamateric receptor systems in PD.
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Figure 1.  Statistical parametric map illustrating an area where BZD receptor binding was 
decreased in PD subjects versus controls in the right dorsal anterolateral prefrontal cortex. 
Voxel t-values corresponding to p<0.01 for the contrast of the PET image data between 
groups appear superimposed on horizontal (left) and sagittal (right) sections from an 
anatomical MRI template generated by averaging spatially normalized MRI images from 
multiple healthy subjects, as provided within SPM software. The PET-and MRI data have 
been spatially transformed to a common spatial array. The crosshair localizes the voxel 
containing the peak t-value, located at x=20, y=48, z= 27 (interpreted as in table 2). The color 
bar indicates the magnitude of the voxel t values. 
 
Figure 2.  Statistical parametric map illustrating the areas where BZD receptor binding was 
increased in PD subjects versus controls in the parahippocampal/hippocampal region. The 
interpretation of the voxel t-values is as in figure 1. The peak t-value, indicated by the 
crosshair, localized to x=30, y= -22, z= -17, interpreted as in table 2.  
 
Figure 3.  Scatter plots of individual BZD receptor BP of subjects with PD and healthy 
controls (HC) in the right dorsal anterolateral prefrontal cortex (DALPFC), the right 
precentral gyrus, the right and left parahippocampal gyrus/hippocampus. Numbers in 
parentheses represent stereotaxic coordinates [x, y, z]. Horizontal lines indicate means. P 
values were derived from two-tailed unpaired t tests. Means (Standard Deviation) of BPs in 
the four ROIs: right DALPFC, PD 2.6 (0.28), HC 3.0 (0.30); right precentral gyrus, PD 2.2 
(0.31), HC 2.7 (0.43); right parahippocampal gyrus, PD 3.0 (0.53), HC 2.6 (0.33); left 
parahippocampal gyrus, PD 2.6 (0.54), HC 2.3 (0.28). 
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Figure 4.  Scores on the PDSS rating scale plotted against mean centered, adjusted BZD 
receptor BP in right dorsal anterolateral prefrontal cortex, and left and right parahippocampal/ 
hippocampal regions of interest. 
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Table 1.  Demographic and Clinical Characteristics of the Study Samples 631 
632  
Characteristic PD Patients 
(N = 15) 
Controls 
(N = 18) 
Sex, Female/Male, No. 11 / 4 13 / 5 
Age, mean (SD) 35.0 (11.6) 35.3 (11.3) 
Age at onset of panic, mean (SD), years 23.6 (10.9) NA 
Panic disorder duration, mean (SD), months 113 (130) NA 
Comorbid Major Depressive Disorder, No. 8 0 
Time spent in past major depressive episodes, 
mean (SD), months 
10.3 (7.5) NA 
Comorbid General Anxiety Disorder, No. 3 0 
Naïve to psychotropic drug-treatment (n) 10 18 
Family history (FH)   
  FH Major depressive disorder 5 0 
  FH Bipolar disorder 1 0 
  FH Anxiety disorders 5 0 
  FH Alcohol dependence 6 0  
Panic Disorder Severity Scale, mean (SD) 
 
9.7 (3.0) 0.0 (0.0) 
Hamilton Anxiety Rating Scale, mean (SD) 
 
11.3 (5.9) 1.4 (3.4) 
Anxiety Sensitivity Index, mean (SD) 45.9 (13.8) 23.4 (4.3) 
Panic Symptom Scale, mean (SD) 27.6 (6.1) 13.1 (0.4) 
Hamilton Depression Rating Scale, mean (SD) 
 
11.5 (7.3) 1.0 (1.7) 
 633 
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Table 2.  Brain regions with a difference in [11C]flumazenil receptor binding 
potentials between patients with panic disorder and healthy controls 
634 
635 
Brain Regions x y z 
coordinatesc 
t-values 
Healthy Controls > All Patients with Panic Disorder 
R dorsal anterolateral prefrontal cortex 20, 48, 27 5.74a 
R frontal polar cortex 30, 53, 8 4.31 
R dorsolateral prefrontal cortex 36, 34, 20 3.42 
R precentral gyrus 32, -7, 50 4.52b 
R postcentral gyrus 44, -16, 34 3.72 
R superior temporal gyrus 65, -40, 8 4.12 
L precentral gyrus -28, -17, 52 3.92 
 -36, -5, 46 3.84 
L dorsal anterolateral prefrontal cortex -18, 42, 27 3.84 
Anterior cingulate gyrus -4, 26, 19 3.40 
L superior occipital gyrus -26, -85, 19 3.72 
R superior parietal cortex 22, -68, 37 3.22 
All Patients with Panic Disorder > Healthy Controls 
R parahippocampal gyrus/ ventral hippocampus 30, -22, -17 4.79a,b 
L parahippocampal gyrus/ ventral hippocampus -26, -24, -16 3.33b 
L dorsolateral prefrontal cortex -40, 39, 33 3.40 
Regions were derived from contrast analyses comparing flumazenil binding potential 
between controls and patients. All results were significant at puncorrected<0.001. 
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a Voxel-level corrected p value significant at p<0.05 after applying family wise-error 
corrections for multiple testing  
638 
639 
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642 
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645 
b Cluster-level, corrected p value < 0.001 after applying the cluster test for multiple testing 
c Coordinates correspond to the stereotaxic array of Talairach and Tournoux (1988), and 
denote mm from the origin (anterior commissure) with positive x indicating right of midline, 
positive y indicating anterior, and positive z indicating dorsal to a plane containing both the 
anterior and posterior commissures. 
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Table 3.  Brain regions with a difference in [11C]flumazenil receptor binding 
between patients with panic disorder alone (N=7) and healthy controls 
646 
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Brain Regions x y z 
coordinates 
t-values 
Healthy Controls > Patients with Panic Disorder Alone 
R frontal polar cortex 28, 51, 10 4.55 
R dorsal anterolateral prefrontal cortex 20, 48, 23 3.95 
 18, 33, 35 3.67 
L frontal polar cortex -28, 51, 3 3.61 
L dorsal anterolateral prefrontal cortex  -22, 42, 22 3.37 
L superior frontal gyrus -16, 16, 45 2.41 
Infralimbic cortex -8, 11, -17 2.89 
 4, 9, -16 2.85 
Patients with Panic Disorder Alone > Healthy Controls 
R parahippocampal gyrus/ventral hippocampus 22, -26, -14 3.58 
R inferior temporal gyrus 40, -66, 0 2.81 
Regions were derived from contrast analyses comparing flumazenil BP between 
patients and controls. The models included age and gender as covariates. All results 
were significant at uncorrected P<0.005. 
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Table 4.  Brain regions with a difference in [11C]flumazenil receptor binding in 
patients with panic disorder and comorbid major depression (N=8) 
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Brain Regions x y z 
coordinates 
t-values 
Healthy Controls > Patients with Panic Disorder and Major Depression 
R doral anterolateral prefrontal cortex 20, 52, 23 4.21 
L doral anterolateral prefrontal cortex -18, 52, 23 2.89 
R precentral gyrus 30, -11, 50 3.73 
L precentral gyrus -26, -22, 58 3.03 
R insula 38, -23, 9 2.93 
R superior parietal cortex 20, -58, 43 2.88 
Patients with Panic Disorder and Major Depression > Healthy Controls 
L medial parietal cortex -12, -34, 52 2.84 
R middle temporal gyrus 42, -36, -4 3.06 
Patients with Panic Alone > Patients with Panic Disorder and Major Depression 
R postcentral gyrus 30, -28, 46 3.62 
R parahippocampal gyrus 20, -28, -15 2.97 
Patients with Panic Disorder and Major Depression > Patients with Panic Alone 
R middle temporal gyrus 42, -36, -4 3.45 
L posterior orbital cortex -14, 12, -17 3.28 
Infralimbic cortex -2, 9, -4 3.13 
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Regions were derived from contrast analyses comparing flumazenil BP between 
patients and controls. The models included age and gender as covariates. All results 
were significant at uncorrected P<0.005. 
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